Immunoblots confirmed previous results in XBP1 isoforms when comparing non-tumourigenic, Oestrogen receptor positive (ER+) and triple negative breast cancer cell lines (MCF10A, MCF7 and MDA-MB-231, respectively) (Fig. 3a). Here, XBP1 is linked to triple-negative breast carcinoma.